Sponsor

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.

Clinical research sponsor

Published trials11

Recruiting shown2

Roles1

SourceClinicalTrials.gov

Clinical trials

11 shown

Phase Ib Study of Efsubaglutide Alfa Injection in Obese AdolescentsNCT07693426 · lead sponsor · 2026-07-16

RECRUITING

The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity（SPARKLE）NCT07114419 · lead sponsor · 2025-08-25

RECRUITING

A Bridging Study of Efsubaglutide Alfa in Healthy Adults in BrazilNCT07518121 · lead sponsor · 2026-06-01

NOT_YET_RECRUITING

Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D PatientsNCT06900075 · lead sponsor · 2025-07-30

NOT_YET_RECRUITING

The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)NCT06921486 · lead sponsor · 2025-03-31

ACTIVE_NOT_RECRUITING

A Study of 3mg Once Every Two Weeks Administration of Efsubaglutide Alfa Injection in Type 2 Diabetes Patients.NCT06849843 · lead sponsor · 2024-12-18

COMPLETED

A Study of the Efficacy and Safety of Efsubaglutide Alfa in Overweight or Obesity PatientsNCT06732960 · lead sponsor · 2024-04-21

COMPLETED

A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients On Metformin Treatment(SUPER-2)NCT04998032 · lead sponsor · 2021-10-12

COMPLETED

A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients(SUPER-1)NCT04994288 · lead sponsor · 2021-08-03

COMPLETED

A Study of Supaglutide in Chinese Type 2 Diabetes PatientsNCT04314622 · lead sponsor · 2020-04-14

COMPLETED

A Study of the Efficacy and Safety of Supaglutide in Healthy ParticipantsNCT03745885 · lead sponsor · 2018-12-04

COMPLETED

Sponsor roles

lead sponsor11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.